Reference : L'etude clinique du mois. L'etude EUROPA: protection cardio-vasculaire avec le perind...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/10583
L'etude clinique du mois. L'etude EUROPA: protection cardio-vasculaire avec le perindopril chez les patients avec coronaropathie stable.
French
[en] Clinical study of the month. The EUROPA study: cardiovascular protection with perindopril in patients with stable coronary heart disease
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Legrand, Victor mailto [Centre Hospitalier Universitaire de Liège - CHU > > Cardiologie >]
2003
Revue Médicale de Liège
58
11
713-6
Yes (verified by ORBi)
National
0370-629X
Belgium
[en] Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Coronary Artery Disease/complications ; Double-Blind Method ; Female ; Heart Arrest/etiology/prevention & control ; Humans ; Male ; Middle Aged ; Myocardial Infarction/etiology/prevention & control ; Perindopril/therapeutic use ; Placebos ; Risk Factors ; Treatment Outcome
[en] The multicentre placebo-controlled double-blind "EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease" (EUROPA) assessed whether the angiotensin-converting-enzyme inhibitor perindopril reduces cardiovascular risk in a population with stable coronary heart disease and no apparent heart failure, whatever the associated cardiovascular risk. Patients were randomly assigned perindopril 8 mg once daily (n = 6110) or matching placebo (n = 6108). After a mean follow-up of 4.2 years, a relative risk reduction of 20% (95% CI 9-29, p = 0.0003) was observed in the combined primary endpoint (cardiovascular death, myocardial infarction, or cardiac arrest) in the group treated with perindopril as compared to placebo. About 50 patients needed to be treated for a period of 4 years to prevent one major cardiovascular event. This benefit was consistent in all predefined subgroups. According to these results, treatment with perindopril, on top of other preventive medications, should be considered in all patients with stable coronary heart disease.
Researchers ; Professionals
http://hdl.handle.net/2268/10583
http://www.rmlg.ulg.ac.be

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
200311_13.pdfNo commentaryPublisher postprint436.67 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.